The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease.
about
Neurogenic bowel dysfunction in patients with spinal cord injury, myelomeningocele, multiple sclerosis and Parkinson's diseaseImproving the oral bioavailability of beneficial polyphenols through designed synergies.Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems.Visuomotor adaptation in Parkinson's disease: effects of perturbation type and medication state.Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease.Effects of dietary factors on levodopa pharmacokinetics.Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy.BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated miceSubthalamic nucleus neuronal firing rate increases with Parkinson's disease progression.Dopamine modulates reward system activity during subconscious processing of sexual stimuli.Dopamine, Salience, and Response Set Shifting in Prefrontal Cortex.Parkinson's Disease and Its Management: Part 4: Treatment of Motor ComplicationsPerformance of a new meter designed for assisted monitoring of blood glucose and point-of-care testing.Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-enOptimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Novel levodopa formulations in the treatment of Parkinson's disease.Using predrugs to optimize drug candidates.Improving L-dopa therapy: the development of enzyme inhibitors.Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study.Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease.Levodopa in Mucuna pruriens and its degradation.Levodopa Withdrawal Presenting as Fever in a Critically Ill Patient Receiving Concomitant Enteral Nutrition.Altered Functional Connectivity Density in Subtypes of Parkinson's Disease.Mathematical insights into the effects of levodopa.Dosage-dependent non-linear effect of L-dopa on human motor cortex plasticity.A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.Pilot dietary study with normoproteic protein-redistributed plant-food diet and motor performance in patients with Parkinson's disease.Effects on locomotion, muscle, bone, and blood induced by a combination therapy eliciting weight-bearing stepping in nonassisted spinal cord-transected mice.Microelectrodes with gold nanoparticles and self-assembled monolayers for in vivo recording of striatal dopamine.Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.Signaled drug delivery and transport across the blood-brain barrier.Interference Assessment of Various Endogenous and Exogenous Substances on the Performance of the Eversense Long-Term Implantable Continuous Glucose Monitoring System.EEG Microstates Change in Response to Increase in Dopaminergic Stimulation in Typical Parkinson's Disease Patients
P2860
Q27012533-27E04300-2DEE-411A-AF56-CD577C661E60Q33646033-BA88929D-9789-4558-ADC7-AEEC12A315A0Q33654487-237E18F3-D820-4150-877C-BB57B035FF1AQ33708265-836B0372-5C48-4EB1-85D5-15FD58CDEEFAQ33843079-A4330F76-C6C2-4D9E-8F62-DFBA6FC87928Q34109657-34F07666-CCCD-4776-BD95-7047072B8129Q34550037-1F267C90-F374-4676-8F02-BA472C84D51CQ34762041-09349D12-D431-4432-B510-6BE24699B4EFQ35150956-1C0CCD09-A805-429F-88CB-46010F9F5C7AQ35982273-6508A49C-6A8E-4A01-8D28-C154ED4C65B1Q36098760-CE637CA5-F54E-4E22-BC48-8CE919B1AB40Q36251899-E112CF01-F78C-4C9C-85AF-CD53C47C8944Q37080644-595E4170-3649-4A81-8E20-754F92D44C5CQ37275476-8BFC83ED-964A-4D49-AAA6-13FBF99EB4B0Q37979869-8751B352-D4B4-4163-8BF3-63961055FCCAQ38178754-2AEAE1E2-4EAE-4611-96F6-E37E9B6D3DFDQ38243993-935BD02B-4C76-434E-A11B-9AD8EF19080AQ38261811-43752841-D3AA-4273-ABB9-4ECDB5E4C717Q38374505-FBE35304-9F8F-4B34-89C9-F40C98F6D263Q38969500-D091CE82-3D47-49D1-99FD-2E1DECB40693Q39172080-FCF4D95D-35DC-41D5-B12D-9A43187D47A2Q39371128-F1940734-508C-40B2-A385-597CFB310A85Q40121476-9C5599BC-23B3-445A-A94B-95EECE042DE1Q42097113-8055E912-9C8C-455A-87E0-9D913C41CC22Q42224924-3C99372E-C07C-4A98-B386-25A1E6D710EFQ42957367-AB78CE6A-540B-4777-85C7-F4AD36B1CF3CQ46059323-48F2279B-DC02-42F5-A1AD-C65C6920B918Q46654301-803A70D9-F38E-4778-912A-E0F167B1D907Q47409582-045A5B9D-03E4-4C8B-8AEA-386408485926Q48518763-A4F14518-05FD-47F2-AEB3-A5880DC1A424Q48880365-8302006E-3045-464B-B5EF-010973B68474Q50240894-30037432-EC69-4F40-91B6-48AE121D36B7Q55344468-844ECBA5-4848-42F6-80C1-5522410D74C7Q58122162-CE4FAA3B-6E50-429B-9F39-C5281511393A
P2860
The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The pharmacokinetics and pharm ...... atment of Parkinson's disease.
@en
The pharmacokinetics and pharm ...... atment of Parkinson's disease.
@nl
type
label
The pharmacokinetics and pharm ...... atment of Parkinson's disease.
@en
The pharmacokinetics and pharm ...... atment of Parkinson's disease.
@nl
altLabel
The Pharmacokinetics and Pharm ...... reatment of Parkinsons Disease
@en
prefLabel
The pharmacokinetics and pharm ...... atment of Parkinson's disease.
@en
The pharmacokinetics and pharm ...... atment of Parkinson's disease.
@nl
P1476
The pharmacokinetics and pharm ...... atment of Parkinson's disease.
@en
P2093
Soo-Peang Khor
P304
P356
10.2174/157488407781668802
P577
2007-09-01T00:00:00Z